JAZZ Pharmaceuticals stocks have jumped to all time highs, up more than 20% on Monday, after the company reported that the company is preparing to launch a new generation of antibiotic treatment.
The company’s shares rose as high as $60.40, after reports that the antibiotic-manufacturing company is working on a new treatment for colitis, which affects 1 in 2 Americans, according to a Wall Street Journal report.
The new treatment is slated to be released in 2019, a year before the year in which many prescription drugs are scheduled to expire.
JAZz has also been one of the largest beneficiaries of a $2 billion deal by Pfizer and Merck that will allow them to develop new antibiotics and vaccines, which the companies hope will provide relief to the country’s rising epidemic.
Pfizer, which is one of JAZs biggest shareholders, will pay $4 billion for the antibiotic maker, which will be one of five such deals that Pfizer has struck in recent months.
The other five include the $1.5 billion deal announced by Pfogenix and Pfizer’s acquisition of Cephalon Therapeutics.
Jazz Pharmaceuticals shares have risen more than 8% so far this year.
The stock is up more like 40% this year, compared with the Dow Jones Industrial Average.
Jaxa shares have jumped more than 7% so to date, after news of the drug maker’s drug approval came out.
The pharmaceutical company announced in December that it was buying a controlling stake in Jaxar for $4.7 billion, giving it a majority stake in the company.
The deal is part of a deal to sell Jaxab, a joint drug development program with Pfizer.
In 2018, Jaxan said it would be launching a new antibiotic treatment, called Pravo, which could help treat colitis.
The drug will also be marketed under the name Pravan, and Pfizers plans to start selling the drug in 2019.
In addition to the Pfizer deal, Jazza Pharmaceuticals is also set to purchase a controlling interest in the Biocon-Nasdaq Biopharmaceuticals, according to a person familiar with the matter.
The acquisition was approved last month by the U.S. Federal Trade Commission, the person said.
Bancorp is also looking to acquire Jaxxa in 2018.
The San Diego-based investment firm, which has a $1 billion portfolio, also owns stakes in two other pharmaceutical companies: AstraZeneca and Gilead Sciences.
While the Pfizers deal was welcomed by some pharmaceutical companies, there were concerns that the new treatment could be too expensive for some patients.
Pfizer and AstraMeds have been criticized by some experts for the cost of the new treatments, which cost between $100 and $200 per pill.
In August, former FDA Commissioner William Breuer raised the prospect of drug makers cutting off funding to pharmaceutical companies that fail to produce new drugs for certain illnesses.
“If we have a drug that fails to go to market in a timely manner, then there’s a danger that this drug will go nowhere,” Breuer said, according the Wall Street Times.
While Pfizer had been expected to receive approval for the new drug in the near future, the company will be delayed until 2018 and could not give an estimate for when it will be ready.
Pfogeniz said it was not sure when it would begin testing the new antibiotics, but that it expected to begin clinical trials this year and could begin selling them by the end of 2019.